139 related articles for article (PubMed ID: 20080315)
1. Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care.
Jacob S; Hovey E; Ng W; Vinod S; Delaney GP; Barton MB
Lung Cancer; 2010 Sep; 69(3):307-14. PubMed ID: 20080315
[TBL] [Abstract][Full Text] [Related]
2. Estimation of an optimal chemotherapy utilisation rate for cancer: setting an evidence-based benchmark for quality cancer care.
Jacob SA; Ng WL; Do V
Clin Oncol (R Coll Radiol); 2015 Feb; 27(2):77-82. PubMed ID: 25455844
[TBL] [Abstract][Full Text] [Related]
3. Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care.
Jacob S; Ng W; Asghari R; Delaney GP; Barton MB
Eur J Cancer; 2009 Sep; 45(14):2503-9. PubMed ID: 19527926
[TBL] [Abstract][Full Text] [Related]
4. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
Ng W; Jacob S; Delaney G; Barton M
Eur J Cancer; 2009 Aug; 45(12):2150-9. PubMed ID: 19285857
[TBL] [Abstract][Full Text] [Related]
5. Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidence-based benchmark for the best-quality cancer care.
Ng W; Delaney GP; Jacob S; Barton MB
Eur J Cancer; 2010 Mar; 46(4):703-12. PubMed ID: 20034784
[TBL] [Abstract][Full Text] [Related]
6. Estimation of an evidence-based benchmark for the optimal endocrine therapy utilization rate in breast cancer.
Fong A; Ng W; Barton MB; Delaney GP
Breast; 2010 Oct; 19(5):345-9. PubMed ID: 20223666
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in rectal cancer: variation in utilization and development of an evidence-based benchmark rate of optimal chemotherapy utilization.
Jacob S; Ng W; Asghari R; Delaney GP; Barton MB
Clin Colorectal Cancer; 2011 Jun; 10(2):102-7. PubMed ID: 21859561
[TBL] [Abstract][Full Text] [Related]
8. Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care.
Ng W; Jacob S; Delaney G; Do V; Barton M
Gastroenterol Res Pract; 2015; 2015():753480. PubMed ID: 25883645
[TBL] [Abstract][Full Text] [Related]
9. Estimation of an optimal utilisation rate for palliative radiotherapy in newly diagnosed cancer patients.
Jacob S; Wong K; Delaney GP; Adams P; Barton MB
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):56-64. PubMed ID: 19969443
[TBL] [Abstract][Full Text] [Related]
10. Estimation of an optimal chemotherapy utilisation rate for primary malignant brain tumours: an evidence-based benchmark for cancer care.
Jacob S; Ng W; Delaney GP; Barton MB
Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):48-54. PubMed ID: 20951557
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer resection rate in south Manchester: is it comparable to international standards? Results of a prospective tracking study.
Devbhandari MP; Yang SS; Quennell P; Krysiak P; Shah R; Jones MT
Interact Cardiovasc Thorac Surg; 2007 Dec; 6(6):712-4. PubMed ID: 17704124
[TBL] [Abstract][Full Text] [Related]
12. Differences in practice patterns and costs between small cell and non-small cell lung cancer patients in Japan.
Kuwabara K; Matsuda S; Fushimi K; Anan M; Ishikawa KB; Horiguchi H; Hayashida K; Fujimori K
Tohoku J Exp Med; 2009 Jan; 217(1):29-35. PubMed ID: 19155605
[TBL] [Abstract][Full Text] [Related]
13. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
14. Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia.
Ghandourh W; Holloway L; Batumalai V; Chlap P; Field M; Jacob S
Clin Transl Radiat Oncol; 2022 May; 34():7-14. PubMed ID: 35282142
[TBL] [Abstract][Full Text] [Related]
15. Non small cell lung cancer within the small cell lung cancer radiotherapy field after 11 years.
Munzuroglu F; Erturan S; Oz B; Dincbas FO; Demir G
J BUON; 2009; 14(2):313-6. PubMed ID: 19650185
[TBL] [Abstract][Full Text] [Related]
16. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):682-92. PubMed ID: 15305397
[TBL] [Abstract][Full Text] [Related]
17. A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer.
Mahar AL; Coburn NG; Johnson AP
Lung Cancer; 2014 Nov; 86(2):281-7. PubMed ID: 25267166
[TBL] [Abstract][Full Text] [Related]
18. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
19. Defining the need for radiotherapy for lung cancer in the general population: a criterion-based, benchmarking approach.
Barbera L; Zhang-Salomons J; Huang J; Tyldesley S; Mackillop W
Med Care; 2003 Sep; 41(9):1074-85. PubMed ID: 12972847
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
